Home > DNA/RNA Synthesis & > Cladribine

Cladribine

克拉利宾,克拉屈宾,克拉屈滨,2-CdA,2-chlorodeoxyadenosine

Cladribine (克拉屈滨) 是腺苷脱氨酶（adenosine deaminase）抑制剂，可作用于毛细胞白血病和多发性硬化。

目录号
EY1162
EY1162
EY1162
EY1162
纯度
99.62%
99.62%
99.62%
99.62%
规格
5 mg
10 mg
50 mg
100 mg
原价
180
330
1100
1990
售价
180
330
1100
1990
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Cladribine is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50 of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0 μM - 32 μM

  • 动物实验

    0.7 mM - 3.5 mM腹腔注射给药

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Ma J, et al. BMC Cancer. 2011, 11, 255.

    分子式
    C10H12ClN5O3    		 分子量
    285.69    		 CAS号
    4291-63-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    ≥55 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00938366 Multiple Sclerosis Drug: Cladribine|Drug: Pantoprazole Merck KGaA|Merck Serono S.A., Geneva Phase 1 2008-01-01 2016-03-15
    NCT01013350 Multiple Sclerosis Drug: Cladribine EMD Serono 2009-11-01 2016-10-14
    NCT02115295 Leukemia Drug: Cladribine|Drug: Cytarabine|Drug: Idarubicin|Behavioral: Phone Calls M.D. Anderson Cancer Center Phase 2 2014-05-01 2016-08-10
    NCT02131753 Hairy Cell Leukemia Drug: Cladribine s.c. injection, HCL treatment University of Giessen Phase 2|Phase 3 2004-05-01 2016-10-25
    NCT01602939 Systemic Mastocytosis Drug: Cladribine and pegylated interpheron alpha-2a Hospital Virgen de la Salud Phase 2|Phase 3 2012-05-01 2016-08-26
    NCT01515527 Leukemia Drug: Cladribine|Drug: Cytarabine|Drug: Decitabine M.D. Anderson Cancer Center Phase 2 2012-02-01 2017-02-14
    NCT00002879 Lymphoma Drug: cladribine Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Phase 2 1996-11-01 2016-12-05
    NCT00412594 Leukemia Drug: Cladribine|Drug: Rituximab M.D. Anderson Cancer Center|Genentech, Inc. Phase 2 2004-06-10 2017-01-24
    NCT00126321 Leukemia, Myelocytic, Acute Drug: cladribine University Hospital, Bonn Phase 2 2004-11-01 2010-02-01
    NCT00923013 Hairy Cell Leukemia Drug: Cladribine|Drug: Rituximab National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 2 2008-10-03 2017-02-10
    NCT01473797 Langerhans Cell Histiocytosis of Lung Drug: Cladribine Assistance Publique - Hpitaux de Paris Phase 2 2011-11-01 2016-09-28
    NCT00980395 Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|SLL Drug: rituximab|Drug: bortezomib|Drug: cladribine University of Arizona|National Cancer Institute (NCI) Phase 2 2009-07-01 2016-04-13
    NCT01446900 Chronic Lymphocytic Leukaemia|Small Lymphocytic Lymphoma Drug: Rituximab|Drug: Cladribine European Institute of Oncology Phase 2 2011-01-01 2015-09-28
    NCT02157181 Hairy Cell Leukemia (HCL) Drug: 2CdA +/- Rituximab Jurgen Barth|University of Giessen Phase 2 2004-06-01 2014-06-03
    NCT00053027 Lymphoma Biological: rituximab|Drug: cladribine Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Phase 2 2003-02-01 2016-12-05
    NCT00213135 Multiple Sclerosis, Relapsing-Remitting Drug: Cladribine 5.25 mg/kg|Drug: Cladribine 3.5 mg/kg|Other: Placebo EMD Serono Phase 3 2005-04-01 2014-01-10
    NCT01439750 Mantle Cell Lymphoma Drug: Rituximab|Drug: bortezomib|Drug: Cladribine Milton S. Hershey Medical Center Phase 1|Phase 2 2012-05-01 2017-01-26
    NCT00725985 Multiple Sclerosis Drug: Cladribine|Drug: Cladribine|Drug: Placebo|Drug: Rebif new formulation (RNF) EMD Serono Phase 3 2008-12-01 2013-08-02
    NCT02250937 Acute Myeloid Leukemia|Myelodysplastic Syndrome Drug: Busulfan|Drug: Fludarabine|Drug: Cladribine|Procedure: Stem Cell Transplant|Drug: G-CSF|Drug: Methotrexate|Drug: Cyclophosphamide M.D. Anderson Cancer Center Phase 2 2014-10-27 2017-03-20
    NCT02044796 Acute Biphenotypic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia Drug: Cladribine|Drug: Cytarabine|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Mitoxantrone Hydrochloride Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) Phase 1|Phase 2 2014-01-01 2016-09-26
    NCT00436826 Multiple Sclerosis Drug: Cladribine|Drug: Placebo|Drug: Interferon-beta (IFN-beta) EMD Serono Phase 2 2006-11-01 2013-08-04
    NCT00787969 Lymphoma Biological: rituximab|Drug: cladribine|Drug: temsirolimus|Biological: Filgrastim|Biological: Pegfilgrastim Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Phase 1 2009-04-01 2016-12-02
    NCT00483067 Leukemia Drug: 2-CdA|Drug: Ara-C|Drug: G-CSF (Granulocyte colony-stimulating factor) M.D. Anderson Cancer Center Phase 2 1998-03-01 2012-08-01
    NCT00667329 Lymphoma Drug: 2CdA|Drug: Cyclophosphamide|Drug: Rituximab M.D. Anderson Cancer Center 1999-07-01 2016-09-12
    NCT00656812 Lymphoma of Mucosa-Associated Lymphoid Tissue Drug: Rituximab|Drug: 2-CdA Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche|Lipomed Phase 2 2008-05-01 2013-12-23

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：